Dr. Thomas Ichim

Chief Science Officer

A child prodigy inspired to heal his mother of chronic myeloid leukemia ( CML ), Canadian-born Dr. Thomas Ichim is a world-renowned scientist who has founded or served in a leadership capacity with five biomedical companies — including Batu Biologics, ToleroTech Technology, and Therapeutic Solutions International — and has pioneered new and innovative processes to conquer the deadliest diseases. His researchers and laboratories are on the cutting edge of biologics, immunotherapy, stem cell therapy, nutritional and naturopathic supplements, and other medical approaches that are giving the critically ill a real chance at full recovery.

Dr. Ichim is an ad-hoc editor and sits on several editorial boards. He is an inventor of 250 patents, published or issued. He also has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.

Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, an MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D. in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.